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More than 90% of chondroblastomas contain a heterozygous mutation replacing lysine-36 with methionine-36 (K36M) in the histone H3 variant H3.3. Here we show that H3K36 methylation is reduced globally in human chondroblastomas and in chondrocytes harboring the same genetic mutation, due to inhibition of at least two H3K36 methyltransferases, MMSET and SETD2, by the H3.3K36M mutant proteins. Genes with altered expression as well as H3K36 di-and trimethylation in H3.3K36M cells are enriched in cancer pathways. In addition, H3.3K36M chondrocytes exhibit several hallmarks of cancer cells, including increased ability to form colonies, resistance to apoptosis, and defects in differentiation. Thus, H3.3K36M proteins reprogram the H3K36 methylation landscape and contribute to tumorigenesis, in part through altering the expression of cancer-associated genes.
C
hondroblastomas are locally recurrent primary bone tumors (1) . Recently, it has been reported that one allele of the H3F3B gene, one of two genes encoding histone H3 variant H3.3 (2, 3), is frequently mutated in chondroblastoma (4) . In addition, global reductions of di-and trimethylation of histone H3 at lysine-36 (H3K36me2 and H3K36me3) of endogenous histone H3 in mammalian cells exogenously expressing the H3.3 Lys 36 →Met 36 (H3.3K36M) mutant protein have been observed (5, 6) . However, the mechanism by which the mutant proteins exert their effects on H3K36 methylation of endogenous histones and how the H3.3K36M mutation promotes tumorigenesis of this poorly studied tumor are largely unknown.
We used H3K36me2-and H3K36me3-specific antibodies ( fig. S1 ) to analyze the levels of H3K36me2 and H3K36me3 in three primary human chondroblastomas harboring the H3.3K36M mutation and in three giant cell tumors with the H3.3G34W (Gly 34 →Trp
34
) mutation (table S1 ). H3K36me2 and H3K36me3 were globally reduced in each chondroblastoma specimen, but not in giant cell tumors or normal bone tissues (Fig. 1A) .
We used the CRISPR/Cas9 system (7) to introduce the H3.3K36M mutation into one H3F3B allele ( fig. S2 ) of T/C28a2 cells, which are immortalized human chondrocytes (8) . The levels of H3K36me1, H3K36me2, and H3K36me3 were reduced in two independent mutant cell lines, as compared with methylation levels in parental T/ C28a2 cells (Fig. 1B and fig. S3 ). As determined by mass spectrometric analysis, H3K36me2 was reduced more substantially than H3K36me3 ( fig.  S3, A and B) . No apparent changes were observed in H3K4me3, H3K9me3, H3K27me3, or H4K20me3 (Fig. 1B ). These results demonstrate that the global reduction of H3K36 methylation in tumor tissues results from the expression of H3.3K36M mutant proteins.
To understand how H3.3K36M mutant proteins globally reduce H3K36 methylation, we first tested the ability of a H3.3K36M peptide to inhibit the enzymatic activities of four human H3K36 methyltransferases-SETD2, ASH1L, MMSET/ WHSC1, and NSD1-which catalyze H3K36me1, H3K36me2, and H3K36me3 (9-11). The purified catalytic domains of each enzyme exhibited methyltransferase activities against H3.3-containing mononucleosomes. The H3.3K36M peptide inhibited the activities of MMSET [median inhibitory concentration (IC 50 ) = 67 mM] and SETD2 (IC 50 = 39 mM) in a dose-dependent manner, as compared with the wild-type (WT) H3 peptide ( Fig. 1C and fig.  S4A ). Moreover, H3.3K36M-containing mononucleosomes inhibited the enzymatic activities of MMSET and SETD2 (Fig. 1D) . In contrast, neither the H3.3K36M peptide nor the H3.3K36M mononucleosomes exhibited an inhibitory effect on the activities of ASH1L and NSD1 in vitro ( fig.  S4 ). We also observed that MMSET-but not ASH1L, NSD1, or two subunits of the H3K27 methyltransferase complex PRC2 (Ezh2 and Suz12)-was enriched in H3.3K36M-containing mononucleosomes compared with WT H3.3-containing mononucleosomes (Fig. 1E) . Finally, in a peptide pull-down assay, MMSET and SETD2 bound to the H3.3K36M peptide more efficiently under higher-salt conditions than to the corresponding normal H3 peptide ( fig. S5A ). These results indicate that the H3.3K36M mutant protein inhibits at least two mammalian H3K36 methyltransferases, MMSET and SETD2.
We used chromatin immunoprecipitation coupled with next-generation sequencing (ChIPseq) (12) to identify 29,250 and 13,694 H3K36me2 peaks in T/C28a2 cells and H3.3K36M lines, respectively ( Fig. 2, A and B) . H3K36me2 peaks present in only the H3.3K36M cells were significantly enriched at promoters, gene bodies, and transcription end sites (TESs) ± 2 kilo-base pairs (kbp) (P < 0.01) but showed significant depletion at intergenic regions (P < 0.01), as compared with H3K36me2 peaks in T/C28a2 cells (Fig. 2 , A to C). On average, levels of H3K36me2 in intergenic regions ( Fig. 2D ) and gene bodies (Fig. 2E) were reduced in each of the H3.3K36M mutant lines compared with the WT T/C28a2 cells. The reduction of H3K36me2 in four selected genes and two intergenic regions was confirmed by ChIPpolymerase chain reaction (PCR) (Fig. 2F ).
Depletion of SETD2 had no apparent effect on H3K36me2. In contrast, depletion of MMSET alone or in combination with SETD2 resulted in a marked reduction of H3K36me2, but to a lesser extent than in cells expressing H3.3K36M, as determined from Western blot analysis ( fig. S5 , B and C). Depletion of SETD2 or MMSET did not affect the expression of the three other H3K36 methyltransferases that we tested ( fig. S5D ). Finally, H3K36me2 ChIP-PCR and ChIP-seq results show that depletion of MMSET alone or in combination with SETD2, but not SETD2 alone, led to reduction of H3K36me2 in gene bodies and intergenic regions but to a lesser extent than in H3.3K36M mutant cells (Fig. 2G and fig. S5 , E and F). Together, these results support the idea that the reduction of H3K36me2 in H3.3K36M cells is mediated, at least in part, through the inhibition of MMSET by the H3.3K36M proteins.
Similar numbers of H3K36me3 ChIP-seq peaks were detected in gene bodies from T/C28a2 cells and H3.3K36M mutant cells ( fig. S6A) . However, the amount of H3K36me3 throughout the gene bodies was reduced in each of the two H3.3K36M mutant lines compared with the T/C28a2 cells (Fig. 2H) . Additionally, more than 60% of genes with reduced levels of H3K36me3 also exhibited reduced H3K36me2 (fig. S6B) . The reduction of H3K36me3 is correlated with the reduction of H3K36me2 ( fig. S6C ), which suggests that both H3K36me2 and H3K36me3 are altered to a similar degree within gene bodies of a large fraction of genes. ChIP-PCR experiments confirmed the reduction of H3K36me3 in gene bodies of four selected genes in two H3.3K36M mutant lines ( fig. S6D) . Finally, depletion of SETD2 and MMSET reduced levels of H3K36me3 in gene bodies, with MMSET depletion having a lesser effect than SETD2 depletion (figs. S5, B and C, and S6, E and F). These results indicate that reduced H3K36me3 levels in gene bodies of H3.3K36M mutant chondrocytes are mainly due to SETD2 inhibition, although MMSET inhibition may also contribute.
We also used ChIP-seq to analyze H3K36me2 and H3K36me3 levels in primary chondroblastomas. The H3K36me2 and H3K36me3 chromatin occupancy in gene bodies was reduced in the two chondroblastoma samples that we analyzed ( fig. S7, A and B) . Gene set enrichment analysis (GSEA) (13) indicated that genes with reduced levels of H3K36me2 and H3K36me3 in gene bodies in chondrocyte cell lines were also enriched in the corresponding gene sets from tumor samples ( fig. S7, C and D) . These results indicate that H3.3K36M mutant proteins have similar effects on the reduction of H3K36me2 and H3K36me3 in gene bodies in both primary chondroblastoma samples and chondrocyte cell lines containing the same H3.3K36M mutation.
We used H3.3K36M-specific antibodies ( fig.  S8A ) and three different assays [Western blot, immunofluorescence (IF), and ChIP-seq] to determine how H3.3K36M mutant proteins associate with chromatin. The majority of the H3.3K36M mutant proteins were detected on chromatin, similarly to WT H3, as evidenced by chromatin fractionation and IF assays ( fig. S8, B and C) . H3.3K36M ChIP-seq identified 6162 overlapping peaks between two H3.3K36M mutant lines (Fig.  3A) . H3.3K36M peaks were significantly enriched at promoters, gene bodies, and TESs ± 2 kbp (P < 0.01) but exhibited significant depletion (P < 0.01) at intergenic regions, as compared with randomly shuffled peaks of the same length (Fig. 3B) . Two of these peaks were confirmed using ChIP-PCR (Fig. 3C) . The levels of H3.3K36M mutant proteins correlated with gene expression levels (Fig.  3D) . These results indicate that chromatin localization of H3.3K36M proteins is similar to that of WT H3.3 observed in other cell lines (14, 15) . Furthermore, the levels of H3K36M mutant proteins were higher in genes with reduced H3K36me2 or H3K36me3 levels than in those without changes in H3K36me2 and H3K36me3 (Fig. 3E and fig.  S9A ). Conversely, the levels of H3K36me2 and H3K36me3 were lower within H3.3K36M peak regions than in the surrounding regions (Fig. 3F  and fig. S9 , B and C). The inverse relationship between the levels of H3.3K36M mutant proteins and levels of H3K36me2 and H3K36me3 on chromatin lends support to the idea that the reduction of H3K36me2 and H3K36me3 is at least partly attributable to the inhibition of MMSET and SETD2 by H3.3K36M mutant proteins incorporated into the chromatin.
Gene expression analysis using RNA-seq indicated that the expression of 567 and 799 genes was elevated and reduced, respectively, in two H3.3K36M mutant cell lines compared with parental T/C28a2 cells ( fig. S10A ). In addition, the expression of intergenic regions with reduced levels of H3K36me2 was lower in H3.3K36M cells than in WT cells ( fig. S10B ). GSEA analysis indicated that genes with reduced expression in H3.3K36M mutant chondrocyte lines were significantly enriched among genes with reduced expression in chondroblastoma samples, whereas genes with increased expression were not enriched ( fig. S10, C and D) . A lack of correlation of genes with increased expression between H3.3K36M mutant lines and chondroblastoma samples was probably due to heterogeneity of chondroblastoma samples (table S1) the reduction of H3K36me2 and H3K36me3 and alters gene expression (fig. S11, A and B) . Finally, we observed that genes with reduced levels of H3K36me2 or H3K36me3 within gene bodies exhibited a significant correlation with changes in gene expression in both cell lines (Fig. 4A ) and in chondroblastoma samples ( fig. S11C ). These results suggest that H3K36me2 and H3K36me3 levels are associated with changes in gene expression in both cell lines and tumors. It is known that H3K36me2 and H3K36me3 antagonize H3K27me3 (12, 16) , raising the possibility that changes in the expression of some genes in H3.3K36M mutant cells may also be linked to deregulation of H3K27me3-repressed genes.
We performed Ingenuity Pathway Analysis (IPA) using three gene sets with altered occupancy of H3K36me2 (1143 genes) and H3K36me3 (1359 genes) and altered gene expression (598 genes) in both chondrocytes and chondroblastoma tumor samples. Genes associated with the "Molecular Mechanisms of Cancer" IPA canonical pathway were highly enriched in all three data sets (fig. S12A). Several genes assigned to the "Molecular Mechanisms of Cancer" pathway are known to be involved in DNA repair, differentiation, and apoptosis ( fig. S12 and table S2 ). We investigated whether H3.3K36M mutant chondrocytes display cancer-associated cellular phenotypes, including DNA repair, in which H3K36me3 has a role (17) (18) (19) . As determined by MTT assay, the H3.3K36M mutations did not affect proliferation of chondrocyte cell lines ( fig. S13A ) but increased the ability of these cells to form colonies (Fig. 4B) . Moreover, H3.3K36M mutant chondrocyte cells were less sensitive to staurosporine-induced apoptosis (Fig.  4C ) and formed denser micromasses when placed into chondrocyte differentiation medium ( fig. S13B ). The effect of H3.3K36M mutation on staurosporineinduced apoptosis could be detected at the same time when H3.3K36M mutant proteins were incorporated into chromatin ( fig. S13C) . Finally, the H3.3K36M mutant cells were also defective in homologous recombination ( fig. S13D ) but had no apparent defects in nonhomologous end joining or mismatch repair ( fig. S13, E and F) . Thus, H3.3K36M mutant cells exhibit several cancerassociated cellular phenotypes.
Consistent with differentiation defects, expression of BMP2 and other genes that regulate chondrocyte differentiation (20) was reduced in H3.3K36M cell lines, as determined by analysis of RNA-seq results ( fig. S14A ). In the micromass assays, BMP (bone morphogenetic protein) signaling is required for hypertrophic chondrocyte differentiation (21) . The mRNA levels of BMP2 and SOX9 were reduced in micromass cultures of T/C28a2 cells expressing the H3.3K36M mutant protein, as compared with the parental cell line (Figs. 4D  and fig. S14B ). Consistent with the reduction in gene expression, ChIP-PCR results showed that H3K36me2 and H3K36me3 occupancy of BMP2 was reduced during differentiation (Fig. 4, E and  F) . In addition to genes involved in differentiation (BMP2 and RUNX2), the expression of two genes involved in homologous recombination (BRCA1 and ATR) was reduced in H3.3K36M mutant lines, as well as in MMSET-and SETD2-depleted cells ( fig. S14, C and D) . Thus, the cancer-associated cellular phenotypes observed in H3.3K36M mutant cells are caused, at least in part, by alterations in H3K36 methylation and expression of key genes that regulate oncogenesis and chondrogenesis.
Our results show that H3.3K36M mutant proteins are incorporated into chromatin in a manner similar to incorporation of WT H3.3 and that these mutant proteins inhibit, at minimum, MMSET and SETD2 to reduce H3K36 methylation. Moreover, H3.3K36M mutant proteins affect various H3K36 methyltransferases differently and promote chondroblastoma tumorigenesis, probably through alterations of several cancer-related processes including colony formation, apoptosis, and chondrocytic differentiation.
